Added to YB: 2025-05-12
Pitch date: 2025-05-09
MXCT [bullish]
MaxCyte, Inc.
-15.56%
current return
Author Info
No bio for this author
Company Info
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Market Cap
$168.5M
Pitch Price
$1.80
Price Target
6.75 (+344%)
Dividend
N/A
EV/EBITDA
-1.87
P/E
-3.67
EV/Sales
2.35
Sector
Life Sciences Tools and Services
Category
growth
Beyond the Cell Surface: An Investment Analysis of MaxCyte ($MXCT)
MXCT: Cell engineering platform co for CGT market, w/ electroporation tech, dual revenue model: core biz (instruments/PAs) growing 9% 2024, high-margin SPL licenses w/ $1.95B potential milestones. First FDA approval (Casgevy) but cash burn issue - $174.7M cash but -$10.3M Q1'25 loss. Base DCF $4.15/sh, 5yr target $6.75 (18.9% IRR). Risk: SPL revenue timing, profitability path.
Read full article (24 min)